Despite a global tendency for lower than average success rates from Phase I to approval in the challenging oncology and CNS areas, a recent Citeline study finds top Japanese pharma firms have relatively high rates in these two categories in the US. So what are the factors driving those differences?

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.